Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All about the IP interims! Let's do our homework.
1- B OM planned and revealed though final data differed dramatically.
2-P planned and never revealed. Obviously the data was not good enough. No final data ever announced- just trial failure, in an extended and ugly fiasco dragging out forever.
3-B v C planned- announced Dec 2 2020 PR. The only question is: will we be told the results? If the news is good we will be told, just like B OM. If not, no interim data out. That will be bad news.
as I wrote earlier today: still some hope for B UC and B UP. Such hope is waning because this trial will sink the company if it fails
"planned interim analysis" 10/2/2020 PR IP re B v C
There now, that was not too hard to track down, was it?
Interim data look planned all along for the current trial.
Interim P data also planned and publicized and then never materialized. Or did it?
Sure- planned release of good interim data and suppress the bad results.
Could it be that simple?
lab data were fine, just now meaningless, since all that counts is trial results.
Off the list but you should be very wary of:
Bogus B OM subset data. Also counts as lying with statistics.
Failure to communicate re P debacle
Lying with statistics: P2b graphs and percentages based on small numbers, as if the percentages mattered.
Stoking the all viruses are toast v B nonsense. Maybe instead just get ONE grant or publish some actual data
any references to spleen lesions of any kind vanishing
How did he get B OM interim data then?
Oh yeah=- also it's in Russia.
I bet he can get it. I also suspect that he did and data are not great. Just my suspicions, may be off base.
Do not trust Leo one little bit.
Interim data. It even has a name. You know, like with B OM
Remember?
Ever heard of B OM? interim data never possible? Leo gave interim data for B OM- it turned out wrong as we all recall
A peek at early data from Moscow and St Pete? Totally plausible.
thanks for the reminder. Please update us on all missed predictions
Start maybe with all the promises of trial start in 2020.....wanna mention those too?
the real hard truth- was there a quick look at data after 15 in each group? Expressly denied by CEO. But I doubt that is true. My guess is there was a quick interim look and the data are not good and so nothing is said. Certainly not good enough to move people off placebo and onto B.
Sure he said they did not do it.
Does anyone believe our CEO about this no quick peek?
you are right, I trust him as far as I can throw him. He likes nothing better than to obscure problems and hide bad news.
I am sure he is really busy with BUC drug formulation. If so where is even one detail? I have been hanging onto this stock figuring they had some chance at a UC drug, either the enema +/- oral formulation. Now he wants to push any B UC stuff to 2022, without saying it out loud, of course. By then, if the B v C trial fails, we may have to sell off B UC in a farewell sale. And yes I like the question and response format to make a point.
B OM action- total joke of course. Leo secretly working on drug formulation for B OM? 2 and 1/2 years after data not good enough for any deal? Lipstick on a pig humor.
Alphavirus update: in a forgotten corner of the Narayanan lab at GMU, a grad student is asked to try out B and VEEV, and that is that. Paid for with pennies by IP to the lab. No partner, nothing big or bad, no MERS or SARS true or real updates. Just the usual baloney from the CEO.
And finally we come to : months to wait for B v C data, many months
will only address a few of your concerns, sorry.
B has a long half life and one dose was deemed OK for cellulitis, which usu needs treatment for at least one week. Fine to see how a single dose would work for COVID
Sorta kinda simple to define by sat and CXR and CRP and whatever else one chose. Same day release of many COVID patients- the applies to most of them who come to an ED with COVID. The ED is the usual decision point for them: admit, or not. PCPs just say OK go to the ED if a pt complains of SOB CP etc with COVID. Most go home and they could all get(well the randomized half anyway) IV B one dose
B UC on hold till next year? This is pathetic.
Enrollment in B v C is very very slow and yet NOTHING happening on B UC front. Never any news about B UP from AS either....
walk /chew gum? My problem with IP now is this: what the heck is up with B UC? Cannot move it forward now? Must it wait for 2022?
That is a problem. If B beats C all is well. If not- and there is an excellent chance of failure- will B UC die with the company, sold off as others pick through IP ashes?
beside the point- all that matters is trial success. Leo as this or that means nothing, nothing at all.
It has come down to this one trial.
Can B UC ensure survival if the trial fails, is the only other relevant question ?
I have suggested in this space an ideal treatment group, the sorta kinda sick person with COVID, who ends up in an Emergency Dept, where they could easily be given IV B. Most of them end up with lines and labs and CXR etc. Most were/are discharged.Lots of data to be gained, not so sick yet. Safety a concern? Easier to watch people in hospital? Yes, easier, but much sicker population with widespread COVID by time of enrollment
There were many more of such patients a year ago, but there are still some coming in even now.
Got it. Then you must understand how I feel when I read about "chump change" and very good chance of success of B v C.
Yawn=perfect response to B v C trial enrollment
trial after trial data done. IP still nowhere with recruiting/enrollment. Feels like a fake company rather than a real one.
Recall 4/6/2020-Leo's first talk of a trialB v C.
Sad performance, reflected in the price of a share.
Natasha: wasn't the trial supposed to be finished a week ago?
Boris: Sigh.
Boris:Get ready for patient # 34! We hope to enroll someone today!
****OFFICIAL TRIAL USE ONLY**** Violaters will be poisoned .
Natasha: Boy is this trial moving slowly or what?
Boris: So hard to say. Enrollment could only go more slowly if the trial stopped.
But why should I have to wait for all the money to flow in? You mean the stock is dead until fall 2021 when the trial is done? And if the trial fails the company is....gone?
If the science is so spectacular then why aren't Narayanan and Bakovic and DeGrado getting a ticker tape parade somewhere near you? And why is the company worthless?
Because there is no guarantee B will work in people with even one of those viruses.
Not even close.
I sent the following email to a couple of close friends.
"There is a small chance of success for IP in its Russian trial of B for C, currently languishing, dragging out as the weeks and months pass, and vaccinations make the need for inpatient treatment less and less necessary. IP has chosen to treat those seriously ill with COVID whereas the lab data suggested most impact was on viral spread. Yes: treatment for those with very widespread disease already, with data from the lab about spread, and no data- none- about B v C anti inflammatory impact.
"CEO comrade Leo keeps up a PR pretense of other big antiviral news coming, B v other viruses. But he has said that for months already and has no grants and no data to back this up.
"That's right. All talk, for many months now, and no grant no partner no other research out yet.
"Just idle chatter, as time passes and we wait for data, mostly from a corrupt country, mostly from hospitals in Moscow and Leningrad. Maybe a handful from Toledo Ohio, maybe.
"That is where things stand here, many months yet to wait for news that means anything. No need to invest now, and maybe no need ever, but I will write back this summer."
They wrote back: "Wow. So much for the launch of the IP rocket in September 2020. LOL."
So I wrote back: " Yes, best case is some kind of a launch by the end of 2021. And that will take a miracle"
Then, their reply: " Kinda sad. Chump change now for a share and yet not worth a buy for now."
And so I said........
Seriously? The data is out for the scientific community to evaluate and the presentation is an afterthought to a paper in a so-so journal. Nothing special.
Sure, OK- early CRISPR papers appeared in no name journals, too. Will B be another big thing?
Time will tell.
Not to worry- watch out for a big- very big-$12,500 to Bakovic lab at GMU for B-VEEV
LOL
Not even chump change: I keep trying to follow that big money flowing to B for viral research and treatment...
but there is none
Let's follow the money folks! B v C lab data out from your friends at GMU RBL. More money to them yet? Maybe in the form of a juicy big grant? Or from big Pharma? Not that we have seen.
Umm, no. Not a nibble.
Not even a bit.
No money to follow.
My bet? Next money to follow will be another Bakovic lab payment from you and me(shareholders) for her alphavirus VEEV research. You know, sorta like we paid her $30,000 for B v C stuff last summer.
You all remember that right?
Get ready for some pathetic chump change to follow to her lab-
follow the money LOL
Precisely on point- follow the money. No grant B for other viruses and for other corona viruses, even though Leo talked up the grants MONTHS ago.
You are so right- follow the money.
And it leads nowhere.
one hopes the recipients are not overwhelmed by irrational exuberance and can think for themselves.
Good grief.
Just 87 to go! Isn't this exciting? Maybe if the next pandemic is an alpha virus the company will be better positioned.
Pray for a miracle, pray for B to help with C.
It will take a miracle rather than a chump change beat down, by the way-
Patient 33! IP PR 4/7/2021. We here at IP are proud to announce the we have enrolled a few more patients. And we will continue to do so. Because things are moving at such a slow pace-glacial, is that about right?-we will PR each and every patient enrollment.
VEEV Bakovic connection. Leo mentions alphaviruses and GMU researcher Bakovic-you remember, the B lab data paper lead author-has a big interest in this virus(VEEV). Bound to be her lab.
So where is the data?
So go ahead Leo- make us into B-VEEV-ers.
chump change challenge, this trial? There is some statistical chance you are right, but it would be very small. But it is fun to ponder, no? B trounces C even in very sick hospitalized patients? Too bad they could not get the trial done any sooner, then. After hundreds of thousands already died. It will be a shame if B is that efficacious, given what has happened.
Chump change does accurately describe something, at least.
that would be the share price of IP, unfortunately.
Please, anything but know what you own. When it is not even vaguely possible with IP.
Gee, if B vs all viruses is so important, where is the evidence? IP touted this many months ago already - NO GRANT and NO other data.
Did Bakovic et al just bury all their key findings at GMU?
the data is so mind-blowing that is suppressed and hidden and classified
What a joke- we do not even have any clue if B beats C in the current trial. Let alone any of the other stuff.
Surely you jest. as if such funds are tracking this lousy penny stock.
If Leo's irrationally exuberant nonsense PRs do not bother you, better for you. I find them pointless
And offensive.
Oh really? If the trial fails how much more research will be done with B vs other viruses?
And where is any data, any at all, that Leo keeps hinting at? Totally bogus pretense.
None, is the obvious answer
Any of that research is meaningless without more clinical data. No grant for any B viral stuff without trial results.
And of course Leo has chosen the wrong trial in the wrong place. And it is on a total slow poke pace-
Leo the tease insults any awake and alert shareholder! PR variation re B v all other viruses. First over the summer it was B may well work with lots of other viruses and we are applying for a grant to look at this.
Then it was narrowed a bit, to MERS and SARS and other coronaviruses might be B targets.
It was hinted there was work being done.
Then yest we hear that other data supports other viruses as targets.
Which is it Leo? Any of the above? All dependent on trial success? Will you describe data from even one other study for other viruses? Will you explain why the GRANTS JUST UP AND DIED- excuse me- were not funded- when it is all so promising?
Likely no substance to monstrous pretense, since it is consistently all talk and no data and no grants, as the weeks and months just pass right on by.
Just more idle speculative nonsense that insults the shareholders. Where is any actual data? Where is any grant if B stomps all those other viruses?
Pathetic
Slo mo vs warp speed. the news is lousy not great. The enrollment could be going more slowly, one supposes, but then it would have to be at a standstill, while for now it is moving, just very slowly.
There, in a nutshell. COVID vaccines and some research at warp speed and IP trial in slow mo.
Sure let's PR every single new patient, why don't they.
30 patients? Lousy. Ugly.
trial barely moving in frigid Russian winter. The market correctly judges this as less than great news.
PR every enrolled patient! Why not!?
It is ONLY 30 so far.
LOL
Sadness rules
One year anniv approaches- trial talk B for C began one entire year ago in a Leo PR. And here we are, doing the wrong trial in the wrong place.
Disappointment reigns.
This is much worse than I ever would have guessed.
hey 30 enrolled!
Ugh. Talk about a sucker punch-
Oof.